Peer-influenced content. Sources you trust. No registration required. This is HCN.
Oncology News Central (ONC)
Osimertinib significantly improved progression-free survival in patients with unresectable stage III EGFR-mutant NSCLC after chemoradiotherapy, with a hazard ratio of 0.16 compared to placebo.
Oncology, Medical September 9th 2024